Oncimmune Holdings plc (AIM:ONC), a leading early cancer detection company developing and commercialising its proprietary EarlyCDT® liquid biopsy platform technology, today announces that it has entered into the licence agreement
First Distribution Agreements Signed for EarlyCDT® Lung Kit (AIM:ONC)
Oncimmune Holdings plc (AIM: ONC.L), a leading early cancer detection company developing and commercialising its proprietary EarlyCDT® platform technology, today announces that it has signed two new exclusive distribution agreements for its EarlyCDT®-Lung